PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 27418820-0 2016 Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD. Ipratropium 23-42 COPD Homo sapiens 141-145 28824036-1 2017 BACKGROUND: Inhaled anticholinergics such as ipratropium bromide (IB), when administered with beta2-agonists, are effective in reducing hospital admissions of children presenting to the emergency department with moderate to severe asthma. Ipratropium 45-64 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 94-99 28824036-1 2017 BACKGROUND: Inhaled anticholinergics such as ipratropium bromide (IB), when administered with beta2-agonists, are effective in reducing hospital admissions of children presenting to the emergency department with moderate to severe asthma. Ipratropium 66-68 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 94-99 30715829-15 2016 There Is little evidence that ipratropium, an inhaled short-acting anti-muscarinic bronchodilator, improves COPD symptoms. Ipratropium 30-41 COPD Homo sapiens 108-112 28990234-6 2018 Of these events only LRTI was significant for Atrovent naive patients [ID1 /IDR = 1.42 (99% CI: 1.04, 1.95)]. Ipratropium 46-54 inhibitor of DNA binding 1, HLH protein Homo sapiens 72-75 27676604-4 2017 Overexpression of OCTs or MATEs in HEK293 cells resulted in an up to 63-fold increase in the uptake of ipratropium (Km of 0.32 mum to OCT2 and Vmax of 3.34 nmolxmg protein-1xmin-1 to MATE1). Ipratropium 103-114 solute carrier family 22 member 2 Homo sapiens 134-138 27676604-4 2017 Overexpression of OCTs or MATEs in HEK293 cells resulted in an up to 63-fold increase in the uptake of ipratropium (Km of 0.32 mum to OCT2 and Vmax of 3.34 nmolxmg protein-1xmin-1 to MATE1). Ipratropium 103-114 solute carrier family 47 member 1 Homo sapiens 183-188 27676604-5 2017 The transcellular transport of ipratropium was 16-fold higher in OCT2-MATE1 and 10-fold higher in OCT1-MATE1 overexpressing compared to control MDCKII cells. Ipratropium 31-42 solute carrier family 22 member 2 Canis lupus familiaris 65-69 27676604-5 2017 The transcellular transport of ipratropium was 16-fold higher in OCT2-MATE1 and 10-fold higher in OCT1-MATE1 overexpressing compared to control MDCKII cells. Ipratropium 31-42 solute carrier family 47 member 1 Homo sapiens 70-75 27676604-5 2017 The transcellular transport of ipratropium was 16-fold higher in OCT2-MATE1 and 10-fold higher in OCT1-MATE1 overexpressing compared to control MDCKII cells. Ipratropium 31-42 solute carrier family 22 member 1 Homo sapiens 98-102 27676604-5 2017 The transcellular transport of ipratropium was 16-fold higher in OCT2-MATE1 and 10-fold higher in OCT1-MATE1 overexpressing compared to control MDCKII cells. Ipratropium 31-42 solute carrier family 47 member 1 Homo sapiens 103-108 27676604-6 2017 Genetic polymorphisms in OCT1 and OCT2 affected ipratropium uptake and clinically relevant concentration of ondansetron and pyrithiamine inhibited ipratropium uptake via MATEs by more than 90%. Ipratropium 48-59 solute carrier family 22 member 1 Homo sapiens 25-29 27676604-6 2017 Genetic polymorphisms in OCT1 and OCT2 affected ipratropium uptake and clinically relevant concentration of ondansetron and pyrithiamine inhibited ipratropium uptake via MATEs by more than 90%. Ipratropium 48-59 solute carrier family 22 member 2 Homo sapiens 34-38 27676604-6 2017 Genetic polymorphisms in OCT1 and OCT2 affected ipratropium uptake and clinically relevant concentration of ondansetron and pyrithiamine inhibited ipratropium uptake via MATEs by more than 90%. Ipratropium 147-158 solute carrier family 22 member 1 Homo sapiens 25-29 27676604-7 2017 This study suggests that OCT1, OCT2 and MATEs may be strongly involved in the renal and extra-renal elimination of ipratropium and other quaternary amine alkaloids. Ipratropium 115-126 solute carrier family 22 member 1 Homo sapiens 25-29 27676604-7 2017 This study suggests that OCT1, OCT2 and MATEs may be strongly involved in the renal and extra-renal elimination of ipratropium and other quaternary amine alkaloids. Ipratropium 115-126 solute carrier family 22 member 2 Homo sapiens 31-35 28035420-10 2017 Our analyses suggested that bisoprolol, celecoxib, and ipratropium bromide, are potential therapeutics for ASL-regulated HCC formation. Ipratropium 55-74 argininosuccinate lyase Homo sapiens 107-110 25278282-0 2015 A comparative study of the beneficial effects of ipratropium and beclomethasone against insulin-induced tracheal tissue contraction in a guinea pig model. Ipratropium 49-60 insulin Cavia porcellus 88-95 25859173-0 2015 Continuous Inhalation of Ipratropium Bromide for Acute Asthma Refractory to beta2-agonist Treatment. Ipratropium 25-44 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 76-81 25859173-1 2015 To present the case of a patient with persistent bronchospasm, refractory to treatment with beta2-agonists, that resolved promptly with continuous inhalation of large dose (1000 mcg/hr) ipratropium bromide, and to discuss the possibility of tolerance to beta2-agonists as the cause for his failure to respond to adrenergic medications. Ipratropium 186-205 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 92-97 25859173-1 2015 To present the case of a patient with persistent bronchospasm, refractory to treatment with beta2-agonists, that resolved promptly with continuous inhalation of large dose (1000 mcg/hr) ipratropium bromide, and to discuss the possibility of tolerance to beta2-agonists as the cause for his failure to respond to adrenergic medications. Ipratropium 186-205 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 254-259 25859173-6 2015 Continuous inhalation of large dose ipratropium bromide may be an effective regimen for the treatment of patients hospitalized with acute asthma who are deemed to be nonresponsive and/or tolerant to beta2-agonist therapy. Ipratropium 36-55 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 199-204 25937167-6 2015 HeLa OCTN1 was inhibited by spermine, NaCl (Na(+)), TEA, gamma-butyrobetaine, choline, acetylcarnitine and ipratropium but not by neostigmine. Ipratropium 107-118 solute carrier family 22 member 4 Homo sapiens 5-10 25278282-1 2015 OBJECTIVE: To evaluate the acute effects of insulin on airway reactivity and the protective effects of beclomethasone and ipratropium against insulin-induced airway hyperresponsiveness on isolated tracheal smooth muscle in a guinea pig model. Ipratropium 122-133 insulin Cavia porcellus 142-149 24607693-2 2014 Herein, by using a modified protocol, combining pilocarpine with ipratropium bromide, we unexpectedly observed a heretofore-unrecognized distinct cellular population expressing the neuroprogenitor marker doublecortin (DCX) on post insult days (PID) 10, 14 and 18, mainly located in the temporal segment of the hippocampal fissure (hf). Ipratropium 65-84 doublecortin Rattus norvegicus 218-221 24428969-10 2014 Interleukin-4 expression level was significantly higher in the allergic model group than in the control group and significantly decreased by ipratropium bromide (P < .05). Ipratropium 141-160 interleukin 4 Mus musculus 0-13 24428969-11 2014 In contrast, the expression of forkhead box P3 was lower in the allergic model group than in the control group and increased with treatment by ipratropium bromide (P < .05). Ipratropium 143-162 forkhead box P3 Mus musculus 31-46 24428969-13 2014 Expression of substance P and vasoactive intestinal peptide was significantly increased in allergic mice and decreased by ipratropium bromide. Ipratropium 122-141 tachykinin 1 Mus musculus 14-25 22409290-12 2012 The cost-effectiveness studies of tiotropium versus placebo, ipratropium or salmeterol pointed towards a reduction in total COPD-related healthcare costs for tiotropium in many but not all studies. Ipratropium 61-72 COPD Homo sapiens 124-128 23748234-7 2013 CCh-stimulated [(35)S]GTPgammaS binding to Galphaq was inhibited by mAChR antagonists, including scopolamine, ipratropium, atropine, 4-DAMP, pirenzepine, and AF-DX 116, with a rank order of potency consistent with previous studies of M1-expressing cells. Ipratropium 110-121 G protein subunit alpha q Rattus norvegicus 43-50 23656745-8 2013 Nebulised ipratropium bromide (via nebulisation or multidosing via pMDI-spacer combination) should be added if there is a poor response to three doses of beta2-agonist or if the symptoms are severe. Ipratropium 10-29 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 154-159 20962061-8 2011 The K(m) value of rOct2-mediated ipratropium uptake (0.143 +- 0.03 muM) was consistent with that of the high-affinity component. Ipratropium 33-44 solute carrier family 22 member 2 Rattus norvegicus 18-23 21728272-1 2011 BACKGROUND: The addition of ipratropium, a synthetic cholinergic antagonist, to beta2-agonist therapy provides an additive improvement in adult with acute severe asthma and COPD because of increased vagal tone in the airways. Ipratropium 28-39 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 80-85 20962061-9 2011 The OCT/Oct inhibitor corticosterone, at a concentration of 1 muM (IC(50), 1.11 +- 0.20 muM for rOct2-mediated ipratropium transport), inhibited ipratropium by 18.4%, suggesting that rOct2 is involved in renal secretion of ipratropium. Ipratropium 111-122 plexin A2 Homo sapiens 4-7 20962061-3 2011 Uptake of radiolabeled ipratropium in rat kidney slices was significantly inhibited by OCT/Oct substrates including cimetidine, imipramine, and quinidine, but not by organic anion transporter substrates (e.g., p-aminohippuric acid and estrone-3-sulfate). Ipratropium 23-34 plexin A2 Homo sapiens 87-90 20962061-3 2011 Uptake of radiolabeled ipratropium in rat kidney slices was significantly inhibited by OCT/Oct substrates including cimetidine, imipramine, and quinidine, but not by organic anion transporter substrates (e.g., p-aminohippuric acid and estrone-3-sulfate). Ipratropium 23-34 plexin A2 Homo sapiens 91-94 20962061-9 2011 The OCT/Oct inhibitor corticosterone, at a concentration of 1 muM (IC(50), 1.11 +- 0.20 muM for rOct2-mediated ipratropium transport), inhibited ipratropium by 18.4%, suggesting that rOct2 is involved in renal secretion of ipratropium. Ipratropium 111-122 plexin A2 Homo sapiens 8-11 20962061-9 2011 The OCT/Oct inhibitor corticosterone, at a concentration of 1 muM (IC(50), 1.11 +- 0.20 muM for rOct2-mediated ipratropium transport), inhibited ipratropium by 18.4%, suggesting that rOct2 is involved in renal secretion of ipratropium. Ipratropium 111-122 solute carrier family 22 member 2 Rattus norvegicus 96-101 20962061-9 2011 The OCT/Oct inhibitor corticosterone, at a concentration of 1 muM (IC(50), 1.11 +- 0.20 muM for rOct2-mediated ipratropium transport), inhibited ipratropium by 18.4%, suggesting that rOct2 is involved in renal secretion of ipratropium. Ipratropium 145-156 plexin A2 Homo sapiens 4-7 20962061-9 2011 The OCT/Oct inhibitor corticosterone, at a concentration of 1 muM (IC(50), 1.11 +- 0.20 muM for rOct2-mediated ipratropium transport), inhibited ipratropium by 18.4%, suggesting that rOct2 is involved in renal secretion of ipratropium. Ipratropium 145-156 plexin A2 Homo sapiens 8-11 20962061-9 2011 The OCT/Oct inhibitor corticosterone, at a concentration of 1 muM (IC(50), 1.11 +- 0.20 muM for rOct2-mediated ipratropium transport), inhibited ipratropium by 18.4%, suggesting that rOct2 is involved in renal secretion of ipratropium. Ipratropium 145-156 solute carrier family 22 member 2 Rattus norvegicus 96-101 20962061-9 2011 The OCT/Oct inhibitor corticosterone, at a concentration of 1 muM (IC(50), 1.11 +- 0.20 muM for rOct2-mediated ipratropium transport), inhibited ipratropium by 18.4%, suggesting that rOct2 is involved in renal secretion of ipratropium. Ipratropium 145-156 plexin A2 Homo sapiens 4-7 20962061-9 2011 The OCT/Oct inhibitor corticosterone, at a concentration of 1 muM (IC(50), 1.11 +- 0.20 muM for rOct2-mediated ipratropium transport), inhibited ipratropium by 18.4%, suggesting that rOct2 is involved in renal secretion of ipratropium. Ipratropium 145-156 plexin A2 Homo sapiens 8-11 20962061-9 2011 The OCT/Oct inhibitor corticosterone, at a concentration of 1 muM (IC(50), 1.11 +- 0.20 muM for rOct2-mediated ipratropium transport), inhibited ipratropium by 18.4%, suggesting that rOct2 is involved in renal secretion of ipratropium. Ipratropium 145-156 solute carrier family 22 member 2 Rattus norvegicus 96-101 18990976-10 2008 CONCLUSIONS: Our data suggest that, besides their positive effects on respiratory symptoms, budesonide, formoterol, ipratropium bromide, and NAC modulate MRP1 activity in bronchial epithelial cells. Ipratropium 116-135 ATP binding cassette subfamily C member 1 Homo sapiens 154-158 19308904-0 2009 [Association of A/T polymorphism of the CHRM2 gene with bronchodilator response to ipratropium bromide in asthmatic children]. Ipratropium 83-102 cholinergic receptor muscarinic 2 Homo sapiens 40-45 21311689-5 2010 RESULTS: With FSC as the reference, risk for a COPD-related hospitalization and/or emergency department visit was significantly higher for ipratropium (hazard ratio [HR] 1.64, 95% confidence interval [CI] 1.50-1.79) and tiotropium (HR 1.29, CI 1.17-1.41). Ipratropium 139-150 COPD Homo sapiens 47-51 21311689-6 2010 Mean adjusted 12-month COPD-related total health care costs were lower for FSC ($2068, standard deviation [SD] $1190) than for ipratropium ($2841, SD $1858) and tiotropium ($2408, SD $1511, both P <0.05). Ipratropium 127-138 COPD Homo sapiens 23-27 20826145-9 2010 In conclusion, formoterol alone or combined with ipratropium bromide partially protects the lungs against the chronic inflammation and airspace enlargement by reducing neutrophilic infiltration possibly via the inhibition of MMP-9 activity. Ipratropium 49-68 matrix metallopeptidase 9 Rattus norvegicus 225-230 20477218-0 2008 Clinical efficacy and safety of the combination of ipratropium bromide and fenoterol inhaled via the Respimat Soft Mist inhaler for relief of airflow obstruction. Ipratropium 51-70 cytokine dependent hematopoietic cell linker Homo sapiens 115-119 14966821-0 2004 Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat Soft Mist Inhaler vs. a conventional metered dose inhaler plus spacer in children with asthma. Ipratropium 23-42 POC1 centriolar protein A Homo sapiens 79-83 16625543-15 2006 Combination therapy with ipratropium plus a short-acting beta-2 agonist conferred benefits over a short-acting beta-2 agonist alone in terms of post-bronchodilator lung function. Ipratropium 25-36 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 111-117 16625543-17 2006 AUTHORS" CONCLUSIONS: The available data from the trials included in this review suggest that the advantage of regular long term use of ipratropium alone or in combination with a short-acting beta-2 agonist or over a beta-2 agonist alone are small, if the aim is to improve lung function, symptoms and exercise tolerance. Ipratropium 136-147 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 217-223 16129327-4 2005 Ipratropium bromide can be added in the nebulisation, depending on the severity of the attack and the response to beta-2-agonists. Ipratropium 0-19 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 114-120 15500180-4 2004 Anticholinergic bronchodilators, such as ipratropium bromide and especially tiotropium, are first-line anticholinergic agents that can be used alone or in combination with long-acting or short-acting beta2-agonists to achieve these primary goals of COPD treatment. Ipratropium 41-60 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 200-205 15500180-4 2004 Anticholinergic bronchodilators, such as ipratropium bromide and especially tiotropium, are first-line anticholinergic agents that can be used alone or in combination with long-acting or short-acting beta2-agonists to achieve these primary goals of COPD treatment. Ipratropium 41-60 COPD Homo sapiens 249-253 12395958-1 2002 OBJECTIVE: To determine whether a combined formulation consisting of ipratropium and an inhaled beta2 agonist (2-in-1 therapy) leads to lower respiratory-related healthcare use and charges and improved compliance compared with treatment with separate ipratropium and beta2-agonist inhalers (separate inhaler therapy). Ipratropium 69-80 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 267-272 15219176-0 2004 A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. Ipratropium 66-85 COPD Homo sapiens 117-121 15219176-1 2004 BACKGROUND: This is the first comparison of two combination therapies, fluticasone propionate/salmeterol and ipratropium bromide/albuterol (salbutamol), for the treatment of patients with COPD. Ipratropium 109-128 COPD Homo sapiens 188-192 12637127-11 2003 The ICER for ipratropium over placebo was $273.03; for formoterol 12 microg over ipratropium, $1611.32. Ipratropium 13-24 cAMP responsive element modulator Homo sapiens 4-8 12578401-7 2003 Current evidence suggests that long-acting beta(2)-adrenoreceptor agonists such as salmeterol and the new long-acting anticholinergic agent tiotropium bromide are more efficacious than their shorter acting equivalents such as salbutamol and ipratropium bromide in terms of bronchodilation, improved well-being and a reduction in acute exacerbation rates. Ipratropium 241-260 adrenoceptor beta 2 Homo sapiens 43-65 15219176-10 2004 CONCLUSIONS: Short-term treatment with the combined inhaled corticosteroid and long-acting beta(2)-adrenoceptor agonist fluticasone propionate/salmeterol resulted in greater control of lung function and symptoms than combined ipratropium bromide/albuterol bronchodilator therapy, in patients with COPD. Ipratropium 226-245 adrenoceptor beta 2 Homo sapiens 91-111 12796167-1 2003 STUDY OBJECTIVE: This study tests the hypothesis that the administration of multiple doses of inhaled albuterol (A), ipratropium bromide (IB), and flunisolide (F) provides an additional benefit to adults with acute severe asthma compared with the administration of A plus IB (A/IB) or A plus F (A/F). Ipratropium 117-136 ANIB1 Homo sapiens 138-140 11980113-10 2002 CONCLUSION: Severe complication of BA is treated more effectively with combination of beta 2-adrenomimetic with atrovent. Ipratropium 112-120 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 86-92 9532321-7 1998 Both doses of ipratropium bromide nasal spray significantly reduced the hypersecretion associated with PAR, compared with placebo. Ipratropium 14-33 jumping translocation breakpoint Homo sapiens 103-106 11714074-7 2001 Use of nebulized ipratropium/beta2-agonist combination therapy was associated with a pooled 7.3% improvement in forced expiratory volume in 1 sec [95% confidence interval (CI), 3.8-10.9%] and a 22.1% improvement in peak expiratory flow (95% CI, 11.0-33.2%) compared with patients who received beta2-agonist without ipratropium. Ipratropium 17-28 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 293-298 11714074-7 2001 Use of nebulized ipratropium/beta2-agonist combination therapy was associated with a pooled 7.3% improvement in forced expiratory volume in 1 sec [95% confidence interval (CI), 3.8-10.9%] and a 22.1% improvement in peak expiratory flow (95% CI, 11.0-33.2%) compared with patients who received beta2-agonist without ipratropium. Ipratropium 315-326 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 29-34 11718499-5 2001 Ipratropium should be considered in patients who fail or cannot tolerate beta2-agonists. Ipratropium 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 73-78 11605121-4 2001 Using an oscillating PEP-system in the expiratory outlet of a nebulizer does not only increase the bronchodilatory effect of ipratropiumbromide but also shortens by combining inhalation and physiotherapy the time necessary for therapy in those patients. Ipratropium 125-143 prolyl endopeptidase Homo sapiens 21-24 11303413-9 2001 Since the publication of these guidelines, several new pharmacological products have been approved for use in patients with COPD including a combination of an anticholinergic and selective beta 2-adrenergic agonist [ipratropium/salbutamol (albuterol)] and a long-acting beta 2-adrenergic agonist (salmeterol). Ipratropium 216-227 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 189-195 10679537-9 2000 In patients with asthma, however, there was a slight increase in the relative risk of mortality associated with the use of ipratropium (RR 1.24; 95% CI 1.11 to 1.39). Ipratropium 123-134 ribonucleotide reductase catalytic subunit M1 Homo sapiens 136-140 9230720-3 1997 We hypothesized that ipratropium bromide, an anticholinergic agent without vascular effects, should block PAF-induced bronchoconstriction but not interfere with its systemic, neutropenic, and gas exchange effects. Ipratropium 21-40 PCNA clamp associated factor Homo sapiens 106-109 9555617-10 1998 Decrease in Tal score after 15 min meant p < 0.01 for salbutamol-ipratropium and salbutamol vs. ipratropium. Ipratropium 68-79 transaldolase 1 Homo sapiens 12-15 9353399-11 1997 Pretreatment of dogs with inhaled ipratropium bromide (0.01%) slightly, but significantly reduced the increase in lung resistance due to NKA challenge but had no effect on the decrease of dynamic lung compliance or on the respiratory responses to NKA. Ipratropium 34-53 tachykinin precursor 1 Homo sapiens 137-140 9164362-11 1997 CONCLUSIONS: Ipratropium nasal spray 0.03% administered at a dose of 42 micrograms/nostril bid is a safe and effective new therapy for control of anterior rhinorrhea in pediatric patients with PNAR. Ipratropium 13-24 BH3 interacting domain death agonist Homo sapiens 91-94 9400690-8 1997 Thus, nebulized ipratropium bromide imparts a small improvement in lung function when compared with salbutamol alone; however, further studies are needed to determine if multiple doses of combined anticholinergic/beta 2-agonist treatment reduce need for admission. Ipratropium 16-35 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 213-219 7982121-0 1994 Effects of ipratropium bromide on bradykinin nasal provocation in chronic allergic rhinitis. Ipratropium 11-30 kininogen 1 Homo sapiens 34-44 8549206-0 1996 Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD. Ipratropium 69-88 COPD Homo sapiens 115-119 8549208-0 1996 Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD. Ipratropium 69-88 COPD Homo sapiens 115-119 8966503-4 1996 In an overview the action, indications and side effects of beta-2 sympathomimetics, ipratropium bromide, anti-allergens and inhaled steroids are discussed. Ipratropium 84-103 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 59-65 8658369-3 1996 The aim of the present study was to determine the dose of ipratropium bromide aerosol that improves exercise performance using progressive cycle ergometry in patients with stable COPD. Ipratropium 58-77 COPD Homo sapiens 179-183 8658369-12 1996 CONCLUSIONS: A dose of at least four times the standard dose of ipratropium bromide from an MDI with a spacer device was necessary to improve maximal cycle exercise capacity in patients with stable COPD. Ipratropium 64-83 COPD Homo sapiens 198-202 1387041-5 1992 Bradykinin challenge induced mean maximal increases of 57%, 59%, 77% and 72% in NAR on the placebo, terfenadine, ipratropium bromide and terfenadine plus ipratropium bromide pretreatment days respectively. Ipratropium 113-132 kininogen 1 Homo sapiens 0-10 8441333-6 1993 The half-lives in hours were: Ba 679-Hm3: 34.7, -Hm1: 14.6, -Hm2: 3.6; ipratropium-Hm3: 0.26, -Hm1: 0.11, -Hm2: 0.035. Ipratropium 71-82 cholinergic receptor muscarinic 3 Homo sapiens 83-86 1387041-5 1992 Bradykinin challenge induced mean maximal increases of 57%, 59%, 77% and 72% in NAR on the placebo, terfenadine, ipratropium bromide and terfenadine plus ipratropium bromide pretreatment days respectively. Ipratropium 154-173 kininogen 1 Homo sapiens 0-10 1387041-8 1992 Bradykinin nasal challenge caused a mean maximal increase in albumin levels in recovered nasal lavages of 11.5, 13.0, 12.2 and 12.3 times of baseline levels on the placebo, terfenadine, ipratropium bromide and terfenadine plus ipratroprium bromide pretreatment days respectively. Ipratropium 186-205 kininogen 1 Homo sapiens 0-10 2145136-0 1990 A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Ipratropium 31-50 COPD Homo sapiens 104-108 1835292-8 1991 Ipratropium may also be effective when beta 2 agonists are not effective. Ipratropium 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 39-45 1837707-8 1991 2) Inhibitory effects of ipratropium bromide inhalation of ACE inhibitor-induced cough were noted in 83.3% of the patients, but their coughs did not completely disappear. Ipratropium 25-44 angiotensin I converting enzyme Homo sapiens 59-62 1840360-7 1991 One of the advantages of adding ipratropium to nebulised beta-agonist treatment might be that it permits the use of lower doses of beta 2-agonist and thereby reduces the systemic side-effects of the treatment. Ipratropium 32-43 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 131-137 2145136-13 1990 We concluded that for acute exacerbations of COPD, both ipratropium and metaproterenol are effective medications when administered via an MDI attached to a device (Inspirease). Ipratropium 56-67 COPD Homo sapiens 45-49 35563491-9 2022 Human OCT1 transported ipratropium with 5.2-fold higher capacity but 8.4-fold lower affinity than dog OCT1. Ipratropium 23-34 solute carrier family 22 member 1 Homo sapiens 6-10 1696438-0 1990 Influence of antihistamine (astemizole) and anticholinergic drugs (ipratropium bromide) on bronchoconstriction induced by substance P. Ipratropium 67-86 tachykinin precursor 1 Homo sapiens 122-133 1972192-10 1990 Bradykinin-induced stimulation of tracheal ciliary beat frequency is blocked by hexamethonium bromide, ipratropium bromide or indomethacin. Ipratropium 103-122 kininogen 1 Canis lupus familiaris 0-10 34884730-4 2021 All OCT2 substrates cis-inhibited DiASP uptake in OCT2-overexpressing HEK293 cells, with IC50 values ranging from 0.24 microM (for ipratropium) to 2.39 mM (for dopamine). Ipratropium 131-142 solute carrier family 22 member 2 Homo sapiens 4-8 34884730-4 2021 All OCT2 substrates cis-inhibited DiASP uptake in OCT2-overexpressing HEK293 cells, with IC50 values ranging from 0.24 microM (for ipratropium) to 2.39 mM (for dopamine). Ipratropium 131-142 solute carrier family 22 member 2 Homo sapiens 50-54 35569122-10 2022 CMap analysis showed that the small molecules scriptaid, torasemide, dexpropranolol, ipratropium bromide, and harmine were potential negative regulators of TGIF1. Ipratropium 85-104 TGFB induced factor homeobox 1 Homo sapiens 156-161 2971708-8 1988 Ipratropium bromide administration, like VIP administration, significantly raised the PD20 value. Ipratropium 0-19 vasoactive intestinal peptide Homo sapiens 41-44 2943921-6 1986 The age, baseline values of FVC and FEV1, and the increases in FEV1 and 1/Zrs with ipratropium did not differ between the two. Ipratropium 83-94 limb development membrane protein 1 Homo sapiens 74-77 2968227-0 1988 Ipratropium in patients with COPD receiving cholinesterase inhibitors. Ipratropium 0-11 butyrylcholinesterase Homo sapiens 44-58 2968227-1 1988 Three patients with chronic obstructive lung disease (COPD) and myasthenia gravis whose pulmonary symptoms were worsened by therapy with cholinesterase inhibitors were improved by inhaled ipratropium bromide. Ipratropium 188-207 butyrylcholinesterase Homo sapiens 137-151 2968227-5 1988 This experience suggests that ipratropium may be the bronchodilator drug of choice in patients with obstructive lung disease aggravated by cholinesterase inhibitors. Ipratropium 30-41 butyrylcholinesterase Homo sapiens 139-153 3541715-8 1987 However, ipratropium bromide (0.25 mg by nebulizer) significantly inhibited the effect of bradykinin, the PD35 being 0.8 mumol (range, 0.16 to 3.4) and 0.15 mumol (range, 0.047 to 1.15) after active dose and placebo, respectively (p less than 0.05). Ipratropium 9-28 kininogen 1 Homo sapiens 90-100 2962075-5 1987 Studies indicate that ipratropium bromide is effective in some pre-term babies who have airways obstruction following positive pressure ventilation but it can be a useful agent in the first 18 months of life, when beta 2-stimulants are rarely effective. Ipratropium 22-41 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 214-220 2943921-7 1986 Isoproterenol-phenylephrine aerosol following ipratropium produced further increases in FEV1 and 1/Zrs in asthmatic patients but no additive increases in bronchitic patients. Ipratropium 46-57 limb development membrane protein 1 Homo sapiens 99-102 6226224-6 1983 Thus, acetylcholinesterase inhibitor therapy in subjects with myasthenia gravis with airflow limitation led to significant increase in airways resistance that could be completely reversed by the inhalation of the muscarinic receptor blocker ipratropium bromide. Ipratropium 241-260 acetylcholinesterase (Cartwright blood group) Homo sapiens 6-26 3529052-3 1986 Following pretreatment with nebulized ipratropium bromide, VIP infusion caused a significant (p less than 0.02) bronchodilation of 25 l/min. Ipratropium 38-57 vasoactive intestinal peptide Homo sapiens 59-62 2951804-0 1986 Prevention of fog-induced bronchospasm by Duovent and its components (fenoterol, ipratropium bromide) in asthmatics. Ipratropium 81-100 zinc finger protein, FOG family member 1 Homo sapiens 14-17 2951808-0 1986 Prevention of fog-induced bronchospasm by high doses of ipratropium bromide in asthmatics. Ipratropium 56-75 zinc finger protein, FOG family member 1 Homo sapiens 14-17 2861067-1 1985 The aim of this study was to investigate the effects of nebulized ipratropium in patients with acute asthma in order to determine whether it augments the bronchodilator effect of a beta agonist drug. Ipratropium 66-77 amyloid beta precursor protein Homo sapiens 179-185 3157668-6 1985 Ipratropium bromide (0.25 mg by inhalation) significantly (P less than 0.05) reduced the bronchoconstriction (maximum falls 34 +/- 14 and 15 +/- 9% after saline and ipratropium bromide, respectively; means +/- SD n = 6), indicating that it was dependent on a cholinergic vagal reflex rather than on local release of substance P from nerves in the airway. Ipratropium 0-19 tachykinin precursor 1 Homo sapiens 316-327 2882568-2 1986 The studies suggest that the use of a combination of anticholinergic and beta 2-adrenergic drugs is justified, because the dominant mechanism in bronchospasm is the effect of acetylcholine on muscarinic receptors and because ipratropium bromide increases the action of fenoterol, so as to obtain prolonged bronchospasmolytic and antibronchoconstrictive effects with halved doses of beta 2-agonist. Ipratropium 225-244 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 73-79 32707498-5 2020 After treatment with ipratropium bromide (IB) or dexamethasone (DEX), the expression of OCTN1/2 was upregulated compared with that in the CSE-LPS model group, while the expression of inflammatory factors was significantly downregulated. Ipratropium 21-40 solute carrier family 22 member 4 Homo sapiens 88-95 6219156-9 1983 It is concluded that when the anticholinergic drug ipratropium is administered concurrently with an inhaled beta 2 agonist and an oral theophylline derivative, increased bronchodilatation occurs with no detectable additional side effects. Ipratropium 51-62 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 108-114 6461333-2 1982 Ipratropium bromide has not only an anticholinergic effect but also has an attenuating one on the contractile responses induced by serotonin, prostaglandin F2 alpha, histamine and bradykinin, and has a potentiating one on the relaxation responses induced by prostaglandin E2, isoprenaline and adrenaline. Ipratropium 0-19 kininogen 1 Homo sapiens 180-190 6448137-3 1980 As with the beta 2-adrenoceptor agonists, the onset of maximum effect with ipratropium (about 1.5 to 2 hours) is slower than with isoprenaline (although significant bronchodilation usually occurs within seconds or minutes of ipratropium inhalation), and the duration of effect (about 4 to 6 hours) is longer. Ipratropium 75-86 adrenoceptor beta 2 Homo sapiens 12-31 6448137-4 1980 Studies of concomitant use of ipratropium and other agents such as beta 2-adrenoceptor agonists, theophylline, or sodium cromoglycate, have usually shown a greater response in many patients than with single drug therapy, as might be expected from the different mechanisms of action of these groups of drugs. Ipratropium 30-41 adrenoceptor beta 2 Homo sapiens 67-86 6448137-8 1980 Ipratropium may also be useful in the occasional patient in whom side effects such as palpitations or tremor are troublesome with usual inhaled doses of beta 2-adrenoceptor agonists. Ipratropium 0-11 adrenoceptor beta 2 Homo sapiens 153-172 159510-1 1979 The effects of (a) regular use for one week and (b) a single dose of a synthetic anticholinergic (ipratropium bromide) on lung mucociliary clearance and as a bronchodilator was ascertained in a controlled, double-blind, cross-over study in 12 patients with reversible airways obstruction (mean increase in FEV after isoprenaline: 17% range 10-50%). Ipratropium 98-117 FEV transcription factor, ETS family member Homo sapiens 306-309 6216870-0 1981 [Effects of ipratropium bromide in aerosol administration on airway resistance and MEFV curves]. Ipratropium 12-31 MEFV innate immuity regulator, pyrin Homo sapiens 83-87 32707498-5 2020 After treatment with ipratropium bromide (IB) or dexamethasone (DEX), the expression of OCTN1/2 was upregulated compared with that in the CSE-LPS model group, while the expression of inflammatory factors was significantly downregulated. Ipratropium 42-44 solute carrier family 22 member 4 Homo sapiens 88-95 31930755-1 2020 BACKGROUND: Ipratropium bromide (IB), when administered with beta2-agonists, is effective in reducing hospital admissions of children presenting to the emergency department (ED) with severe asthma. Ipratropium 12-31 ATPase H+ transporting V0 subunit a2 Homo sapiens 61-66 31930755-1 2020 BACKGROUND: Ipratropium bromide (IB), when administered with beta2-agonists, is effective in reducing hospital admissions of children presenting to the emergency department (ED) with severe asthma. Ipratropium 33-35 ATPase H+ transporting V0 subunit a2 Homo sapiens 61-66 32027707-6 2020 In both cell models, L-carnitine uptake on the apical side was significantly inhibited by the bronchodilators glycopyrrolate and tiotropium, that hence can be considered substrates of ATB0,+; ipratropium was instead effective on the basolateral side, indicating its interaction with OCTN2. Ipratropium 192-203 solute carrier family 22 member 5 Homo sapiens 283-288 31658507-10 2020 Furthermore, phosphorylated Akt (p-Akt) protein levels increased in CD4+ T cells from both controls and AR patients after coculture with D-U87 cells and decreased after IB treatment. Ipratropium 169-171 AKT serine/threonine kinase 1 Homo sapiens 28-31 31658507-10 2020 Furthermore, phosphorylated Akt (p-Akt) protein levels increased in CD4+ T cells from both controls and AR patients after coculture with D-U87 cells and decreased after IB treatment. Ipratropium 169-171 AKT serine/threonine kinase 1 Homo sapiens 35-38 31658507-13 2020 CONCLUSION: In-vitro cholinergic nerve inhibition with IB decreased AR CD4+ T-cell polarization into Th2 cells partially through an Akt-dependent mechanism. Ipratropium 55-57 AKT serine/threonine kinase 1 Homo sapiens 132-135